Clinical Trial Update: Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating anti-gp100 cells plus ALVAC gp100 vaccine in advanced/metastatic melanoma; the study was terminated with results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Skin Cancer

Drugs mentioned

• ALVAC gp100 Vaccine
• Anti-gp100 Cells

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Melanoma, Skin Cancer | Phase 2 | Status: TERMINATED | Results posted: 2012-04-10